• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

海龟抗菌药代动力学研究综述

Antimicrobial Pharmacokinetic Studies in Sea Turtles: A Review.

作者信息

Egelund Eric F, Jula Alana, Rish Kathleen, Casapao Anthony M

机构信息

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Jacksonville, Florida, USA.

Infectious Disease Pharmacokinetics Laboratory, Gainesville, Florida, USA.

出版信息

J Vet Pharmacol Ther. 2025 Jan;48(1):1-14. doi: 10.1111/jvp.13492. Epub 2024 Nov 12.

DOI:10.1111/jvp.13492
PMID:39530192
Abstract

Sea turtles face various threats to survival, primarily due to human activities, such as bycatch, vessel strikes, pollution, and climate change. Many of these activities can lead to illness or injuries, increasing the risk of infection. Treating infections appropriately and effectively requires knowledge of antimicrobial properties and their ability to eradicate microbes without harm to the sea turtle. Robust pharmacokinetic studies, therefore, are important for appropriate dosing. Herein, we review the studies detailing the pharmacokinetic properties of antimicrobials in sea turtles conducted to date.

摘要

海龟面临着各种生存威胁,主要是由于人类活动,如兼捕、船只撞击、污染和气候变化。这些活动中的许多都可能导致疾病或受伤,增加感染风险。适当且有效地治疗感染需要了解抗菌特性及其在不伤害海龟的情况下根除微生物的能力。因此,强大的药代动力学研究对于适当给药很重要。在此,我们回顾了迄今为止所进行的详细阐述海龟体内抗菌药物药代动力学特性的研究。

相似文献

1
Antimicrobial Pharmacokinetic Studies in Sea Turtles: A Review.海龟抗菌药代动力学研究综述
J Vet Pharmacol Ther. 2025 Jan;48(1):1-14. doi: 10.1111/jvp.13492. Epub 2024 Nov 12.
2
Pharmacokinetics of ceftriaxone in Green sea turtles (Chelonia mydas) following intravenous and intramuscular administration at two dosages.两种剂量静脉注射和肌肉注射后头孢曲松在绿海龟(蠵龟)体内的药代动力学
J Vet Pharmacol Ther. 2019 Jan;42(1):104-110. doi: 10.1111/jvp.12723. Epub 2018 Oct 11.
3
PHARMACOKINETICS OF METRONIDAZOLE IN GREEN (), LOGGERHEAD (), AND KEMP'S RIDLEY () SEA TURTLES AFTER SINGLE ORAL AND INTRAVENOUS DOSES.甲硝唑在绿海龟、蠵龟和肯氏丽龟单次口服及静脉给药后的药代动力学
J Zoo Wildl Med. 2024 Dec;55(4):1049-1055. doi: 10.1638/2024-0012.
4
Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.体外膜肺氧合患者抗感染药物的药代动力学与给药:当前文献综述
Clin Ther. 2016 Sep;38(9):1976-94. doi: 10.1016/j.clinthera.2016.07.169. Epub 2016 Aug 21.
5
Antimicrobial Agent Dosing in Infants.婴儿抗菌药物的给药剂量
Clin Ther. 2016 Sep;38(9):1948-60. doi: 10.1016/j.clinthera.2016.06.017. Epub 2016 Jul 26.
6
Updated antimicrobial dosing recommendations for obese patients.肥胖患者抗菌药物剂量调整的最新推荐。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25.
7
Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration.氟苯尼考在绿海龟(Chelonia mydas)和玳瑁(Eretmochelys imbricata)肌肉注射后的药代动力学特征。
J Vet Pharmacol Ther. 2024 Jul;47(4):300-307. doi: 10.1111/jvp.13441. Epub 2024 Mar 22.
8
Pharmacokinetic characteristics of danofloxacin in green sea (Chelonia mydas) and hawksbill sea (Eretmochelys imbricata) turtles.绿海龟(Chelonia mydas)和玳瑁(Eretmochelys imbricata)海龟中丹诺氟沙星的药代动力学特征。
J Vet Pharmacol Ther. 2022 Jul;45(4):402-408. doi: 10.1111/jvp.13054. Epub 2022 Mar 24.
9
Fishermen Interviews: A Cost-Effective Tool for Evaluating the Impact of Fisheries on Vulnerable Sea Turtles in Tunisia and Identifying Levers of Mitigation.渔民访谈:一种评估渔业对突尼斯脆弱海龟影响并确定缓解措施的经济高效工具。
Animals (Basel). 2023 May 4;13(9):1535. doi: 10.3390/ani13091535.
10
Pharmacokinetics of marbofloxacin in Green sea turtles (Chelonia mydas) following intravenous and intramuscular administration at two dosage rates.两种给药剂量下,静脉注射和肌肉注射后,玛波沙星在绿海龟(蠵龟)体内的药代动力学。
J Vet Pharmacol Ther. 2020 Mar;43(2):215-221. doi: 10.1111/jvp.12832. Epub 2019 Dec 18.

引用本文的文献

1
Sodium glucose transporter 2 inhibitors: Will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?钠葡萄糖协同转运蛋白2抑制剂:这些药物会使患有心脏和肾脏疾病的非糖尿病兽医患者受益吗?
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):1-18. doi: 10.1111/jvp.13472. Epub 2024 Jul 13.